Regeneron Pharmaceuticals Shares Are Trading Lower After Citigroup Cut Its Price Target on the Stock From $895 to $795.

Benzinga03:39

Could The Market Be Wrong About Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Its Attractive Financial Prospects?

Simply Wall St00:36

Goldman Sachs Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,185

Futu NewsJan 14 22:31 · Ratings

BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $950

Futu NewsJan 14 21:34 · Ratings

Regeneron Pharma Is Maintained at Neutral by Citigroup

Dow JonesJan 14 21:19 · Ratings

Regeneron Pharmaceuticals Analyst Ratings

BenzingaJan 14 21:08 · Ratings